Luminex Corporation Company Profile (NASDAQ:LMNX)

Luminex Corporation trades on the NASDAQ under the ticker symbol "LMNX."

Luminex Corporation declared a quarterly dividend on Thursday, May 25th. Investors of record on Friday, June 23rd will be paid a dividend of $0.06 per share on Friday, July 14th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date of this dividend is Wednesday, June 21st. View Luminex Corporation's Dividend History.

Luminex Corporation (NASDAQ:LMNX) issued its quarterly earnings data on Monday, May, 1st. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.12. The firm had revenue of $77.80 million for the quarter, compared to analysts' expectations of $74.25 million. Luminex Corporation had a return on equity of 5.48% and a net margin of 5.00%. The company's revenue was up 23.5% on a year-over-year basis. During the same period last year, the company earned $0.29 EPS. View Luminex Corporation's Earnings History.

6 equities research analysts have issued 1-year price targets for Luminex Corporation's stock. Their predictions range from $18.00 to $27.00. On average, they expect Luminex Corporation's stock price to reach $21.40 in the next twelve months. View Analyst Ratings for Luminex Corporation.

Here are some recent quotes from research analysts about Luminex Corporation stock:

• 1. According to Zacks Investment Research, "Luminex’s Assay business will be its key growth driver over the long term. The company also witnessed favorable tidings at the regulatory-front of late. In this regard, the reimbursement approval of VERIGENE assay in Japan and FDA clearance of Bordetella Assay are noteworthy. We are also optimistic about the company’s products – ARIES and NxTAG RPP – which represent a major revenue opportunity.  Luminex reported stable first-quarter 2017 results, beating the Zacks Consensus Estimates on both lines. Also the weakness in stock price over the past on year has made valuation very compelling. Finally Luminex has a broad product portfolio that comprises of its advanced xMAP, xTAG and MultiCode technology. The company’s large installed instrument base and collaborative agreements with several companies would also help expand the use of its products." (7/17/2017)
• 2. Piper Jaffray Companies analysts commented, "Luminex announced 4Q16 revenue of $72.3M, in line with preliminary results. Adj. EPS of $0.06 missed the Street's $0.13 estimate. Results in the quarter reflect strong consumables growth, somewhat offset by lighter instrument sales. Management reaffirmed FY17 revenue guidance of $295M-$305M and provided 1Q17 revenue guidance in line with the Street ($73M-$75M; Street: $74.2M). Revenue guidance appears achievable, but we believe shares are fairly valued. We remain Neutral with a $19 price target (was $20) based on ~2.1x FY18 EV/Rev (unchanged) on our revised estimates." (2/7/2017)

Some companies that are related to Luminex Corporation include Accelerate Diagnostics (AXDX), Natus Medical Incorporated (BABY), Quidel Corporation (QDEL), ABAXIS (ABAX), Mazor Robotics (MZOR), GenMark Diagnostics (GNMK), LeMaitre Vascular (LMAT), Accuray Incorporated (ARAY), Pacific Biosciences of California (PACB), Corindus Vascular Robotics (CVRS), ViewRay (VRAY), Cytosorbents Corporation (CTSO), Alliance HealthCare Services (AIQ), Viveve Medical (VIVE), Fulgent Genetic (FLGT), IRIDEX Corporation (IRIX), Cogentix Medical (CGNT) and Neovasc Inc (US) (NVCN).

Luminex Corporation's management team includes the folowing people:

• G. Walter Loewenbaum II, Independent Chairman of the Board
• Nachum Shamir, President, Chief Executive Officer, Director
• Harriss T. Currie, Chief Financial Officer, Senior Vice President - Finance, Treasurer
• Richard W. Rew II, Senior Vice President, General Counsel, Secretary
• Nancy M. Fairchild, Senior Vice President - Human resources
• Randall Myers, Senior Vice President - Global Manufacturing and Quality
• Robert J. Cresci, Independent Director
• Stephen L Eck, Independent Director
• Thomas Willard Erickson, Independent Director
• Jimmy Dale Kever, Independent Director

Luminex Corporation's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Thomson Horstmann & Bryant Inc. (0.94%), CWM LLC (0.41%), Fisher Asset Management LLC (0.15%), Eqis Capital Management Inc. (0.10%), Bank of Montreal Can (0.09%) and Aperio Group LLC (0.08%). Company insiders that own Luminex Corporation stock include G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir and Russell W Bradley. View Institutional Ownership Trends for Luminex Corporation.

Luminex Corporation's stock was sold by a variety of institutional investors in the last quarter, including CWM LLC, Bank of Montreal Can, Capstone Asset Management Co. and Creative Planning. Company insiders that have sold Luminex Corporation stock in the last year include G Walter Loewenbaum II and Kevin M Mcnamara. View Insider Buying and Selling for Luminex Corporation.

Luminex Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Aperio Group LLC, Fisher Asset Management LLC, Thomson Horstmann & Bryant Inc., State of Alaska Department of Revenue, Eqis Capital Management Inc., Louisiana State Employees Retirement System and McQueen Ball & Associates Inc.. Company insiders that have bought Luminex Corporation stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex Corporation.

Shares of Luminex Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Luminex Corporation stock can currently be purchased for approximately $20.71.